F. Visco
Impact in
-
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
-
- Cancer Cells and Metastasis
Papers in
- Oncology 5
- PARP inhibition in cancer therapy 3
- HER2/EGFR in Cancer Research 2
- Lung Cancer Research Studies 1
-
- DNA Repair Mechanisms 2
- Co-authors
- Kay Dickersin (4 shared papers)Dennis J. Slamon (3 shared papers)George W. Sledge (2 shared papers)Pamela Klein (2 shared papers)Musa Mayer (2 shared papers)Helene S. Smith (1 shared paper)Jean E. Johnson (1 shared paper)Jennifer A. Pietenpol (1 shared paper)
- Journals
- Annals of Oncology (3 papers)Nature reviews. Cancer (2 papers)Cancer Research (2 papers)Clinical Cancer Research (1 paper)Breast Disease (1 paper)
- Partner nations
- United StatesSouth KoreaSpain
In The Last Decade
F. Visco
15 papers receiving 240 citations
Peers
Comparison fields: 5 of 63
- Cancer Research 31
- Oncology 47
- General Health Professions 44
- Genetics 44
- Pulmonary and Respiratory Medicine 27
Countries citing papers authored by F. Visco
This map shows the geographic impact of F. Visco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Visco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Visco more than expected).
Fields of papers citing papers by F. Visco
This network shows the impact of papers produced by F. Visco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Visco. The network helps show where F. Visco may publish in the future.
Co-authors
The 25 scholars most cited alongside F. Visco, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 77 | |
| 2 | 2002 | 48 | |
| 3 | 1996 | 40 | |
| 4 | 2001 | 32 | |
| 5 | 2024 | 21 | |
| 6 | 2015 | 7 | |
| 7 | 2007 | 5 | |
| 8 | 1998 | 5 | |
| 9 | 2016 | 3 | |
| 10 | 1980 | 3 | |
| 11 | 2025 | 2 | |
| 12 | 2015 | 2 | |
| 13 | 2013 | 2 | |
| 14 | 2025 | 1 | |
| 15 | 1983 | 1 |
About F. Visco
F. Visco is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Genetics and Nuclear and High Energy Physics, having authored 15 papers that have together received 249 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (3 papers), Advanced Breast Cancer Therapies (3 papers), PARP inhibition in cancer therapy (3 papers), DNA Repair Mechanisms (2 papers), Cancer Genomics and Diagnostics (2 papers), Breast Cancer Treatment Studies (2 papers), HER2/EGFR in Cancer Research (2 papers) and Lung Cancer Research Studies (1 paper). The work is most often cited by research in Cancer Research (31 citations), Oncology (47 citations), General Health Professions (44 citations), Genetics (44 citations) and Pulmonary and Respiratory Medicine (27 citations). F. Visco has collaborated with scholars based in United States, South Korea and Spain. Frequent co-authors include Kay Dickersin, Dennis J. Slamon, George W. Sledge, Pamela Klein, Musa Mayer, Helene S. Smith, Jean E. Johnson, Jennifer A. Pietenpol, Lundy Braun and Margaret Mead. Their work appears in journals such as Annals of Oncology, Nature reviews. Cancer, Cancer Research, Clinical Cancer Research and Breast Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.